Fund moves

Boston Scientific (BSX)Migdal Insurance & Financial Holdings Ltd. exited its position 500K shares

Migdal Insurance & Financial Holdings Ltd. exited its position in Boston Scientific, per its Q2 2026 13F.

500K
Prior-quarter shares · no longer reported
Holdings as of
Jun 30, 2026
Filed
Aug 10, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Nov 4, 2025Federal contract · $601K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $601K obligated to date
  2. Dec 23, 2025Federal contract · $493K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $493K obligated to date
  3. Mar 27, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  4. Jun 4, 2026CongressDisclosed partial sale of BSX — reported range $1,001 - $15,000
  5. Jun 5, 2026Congress · 1 personMembers of Congress: 1 purchase, 1 sale
  6. Jul 14, 2026FDARecall: Suture Cinch Long 1pk. Endoscopic tissue approximation device.
  7. Jul 16, 2026Federal contract · $608K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $608K obligated to date
  8. Jul 21, 2026Company filing · Form 8-K · RestructuringAnnounced job cuts, closures or a restructuring“On July 21, 2026, the Board of Directors of Boston Scientific Corporation (the “Company”) approved a new global restructuring program (the “2026 Restructuring Plan”).”
  9. Jul 22, 2026FDARecall: Boston Scientific Corporation StoneSmart Connect Console Contents: (1) Power Cord, (1) Power Adaptor, (1)DVI Cable, (1) DVI to HDMI Cable, (1) DisplayPort Cabl…
  10. Jul 24, 2026FDAFDA device clearance: TheraSphere 360™ Y-90 Management Platform
  11. Jul 24, 2026FDAFDA device clearance: OBSIDIO Conformable Embolic
  12. Jul 24, 2026FDAFDA device clearance: FARADRIVE™ Steerable Sheath (M004PF21M402)
  13. Jul 29, 2026Company filing · Form 8-K · ResultsReported its results
  14. Jul 31, 2026InsiderDirector purchased ~$227K of BSX shares in the open market
  15. Aug 3, 2026Insider · 2 peopleInsiders: 2 purchases (~$9.1M)
  16. Aug 4, 2026FDAFDA device clearance: Navigator™ Flex Ureteral Access Sheath Set
  17. Aug 4, 2026Insider · 3 insiders in a week, 7th time since 2006Director purchased ~$6.8K of BSX shares in the open market
  18. Aug 5, 2026Insider · 3 insiders in a week, 7th time since 2006Director purchased ~$100K of BSX shares in the open market
  19. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS US, Model Number 7260, All Versions (Current 7.8)
  20. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS ANZ, Model Number 7248, All Versions (Current 7.7)
  21. Aug 6, 2026FDARecall: LUX-Dx, LUX-Dx II, LUX-Dx II+ Insertable Cardiac Monitor System, SERVER SW LAT CLARITY DS EU, Model Number 7246, All Versions (Current 7.7)
  22. Aug 6, 20265% stakeFMR LLC reported a passive stake (13G) of 3.1%

What came next

  1. Aug 12, 2026FDAFDA device clearance: EluPro Antibiotic-Eluting BioEnvelope
  2. Aug 18, 2026CongressDisclosed purchase of BSX — reported range $1,001 - $15,000
  3. Aug 21, 2026FDAFDA device clearance: AVVIGO™+ Multi-Modality Guidance System
  4. Aug 24, 2026FDARecall: Imager II Angiographic Catheters M001314001 IMAGER II/5/ST/65/038 BX5; M001314011 IMAGER II/5/ST/100/038 BX5; M001314021 IMAGER II/5/ST/65/035 BX 5; M001314031…
  5. Aug 25, 2026Insider · 13 days before an 8-KDirector purchased ~$100K of BSX shares in the open market
  6. Aug 26, 2026FDAFDA device clearance: LithoVue Elite Digital Flexible Ureteroscope System
  7. Aug 31, 2026CongressDisclosed sale of BSX — reported range $15,001 - $50,000
  8. Sep 3, 2026FDAFDA device clearance: Rezum System
  9. Sep 3, 2026Congress · 1 personMembers of Congress: 3 sales
  10. Sep 4, 2026CongressDisclosed partial sale of BSX — reported range $50,001 - $100,000
  11. Sep 7, 2026Company filing · Form 8-K · Cyber incidentReported a cybersecurity incident“As previously disclosed in a Current Report on Form 8-K filed on August 26, 2026 with the Securities and Exchange Commission, on August 25, 2026, Boston Scientific Corporation (the “ Company ”) identified a cybersecurity incident that affected certain of its information technology systems and resulted in a global disruption to the Company’s operations.”
  12. Sep 9, 2026CongressDisclosed sale of BSX — reported range $50,001 - $100,000
  13. Sep 11, 2026FDAFDA device clearance: SpaceOAR Flex™ System
  14. Sep 21, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On September 21, 2026, Arthur C. Butcher informed Boston Scientific Corporation (the “Company”) that he has decided to retire from his role as Executive Vice President and Group President, MedSurg and Asia Pacific effective as of January 1, 2027.”
  15. Oct 1, 2026Company filing · Form 8-K · Executive change, Other newsChanged a top executive or board member, and reported other company news“On October 7, 2026, Boston Scientific Corporation (the “Company”) announced that Joe Fitzgerald, who currently serves as Executive Vice President and Group President, Cardiovascular, has been promoted to Executive Vice President and Chief Operating Officer of the Company, effective as of January 1, 2027.”
  16. Oct 1, 2026Federal contract · $465K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $465K obligated to date
  17. Oct 1, 2026Federal contract · $524K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $524K obligated to date
  18. Oct 1, 2026Federal contract · $832K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $832K obligated to date
  19. Oct 1, 2026Federal contract · $880K obligatedDepartment of Veterans Affairs awarded Boston Scientific: $880K obligated to date
  20. Oct 1, 2026Federal contract · $1.0M obligatedDepartment of Veterans Affairs awarded Boston Scientific: $1.05M obligated to date
View the official recordSEC Form 13F-HR

How to read SEC Form 13F-HR

Form 13F is the quarterly report in which investment managers that oversee $100 million or more list the US-listed stocks and some other securities they held on the last day of the quarter.

Full guide: What is an SEC Form 13F?

What else is on file for Boston Scientific

For Boston Scientific, OQRO holds 6 insider filings (SEC Form 4 or Form 144), 9 Congress trade reports, 64 fund holdings reports (13F) and 8 federal contract awards dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BSX page.

How this filing works

Other disclosures at Boston Scientific

Everything OQRO holds on this company is on its BSX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

OQRO Pro is a paid subscription. You see the price before you pay

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data